Your browser doesn't support javascript.
loading
In Vitro Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Mycobacterium abscessus Complex.
Cheng, Aristine; Tsai, Yi-Tzu; Chang, Shu-Yuan; Sun, Hsin-Yun; Wu, Un-In; Sheng, Wang-Huei; Chen, Yee-Chun; Chang, Shan-Chwen.
Afiliação
  • Cheng A; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Tsai YT; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chang SY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Sun HY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Wu UI; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Sheng WH; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chen YC; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chang SC; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan changsc@ntu.edu.tw.
Article em En | MEDLINE | ID: mdl-30670428
Infections caused by the difficult-to-treat bacterium Mycobacterium abscessus are increasing in frequency. Rifabutin, in contrast to rifampin, appears to be active in vitro against M. abscessus, especially against clarithromycin-resistant strains. However, explorations for potential synergy between rifabutin and available antimicrobials are currently limited. In vitro synergism between rifabutin and 10 antimicrobials was evaluated in 31 mycobacterial strains by the checkerboard method. The fractional inhibitory concentration index (FICI) was calculated for each rifabutin-based combination. The colony morphology was recorded. Molecular methods for determination of the M. abscessus subspecies and analysis of macrolide resistance were performed by sequencing of the secA1, rpoB, hsp65, erm(41), and rrl genes. Rifabutin yielded an MIC50 of 16 mg/liter (range, 2 to 32 mg/liter) against 26 clinical M. abscessus isolates (comprising 13 M. abscessus subsp. abscessus and 13 M. abscessus subsp. massiliense isolates) and 5 reference strains, including M. abscessus subsp. abscessus ATCC 19977, M. abscessus subsp. bolletii BCRC 16915, M. abscessus subsp. massiliense BCRC 16916, M. chelonae ATCC 35752, and M. peregrinum ATCC 700686. Significant synergism, classified by an FICI of ≤0.5, was demonstrated for the combinations of rifabutin and imipenem in 100% of M. abscessus subsp. abscessus and 69% of M. abscessus subsp. massiliense isolates, and significant synergism for rifabutin and tigecycline was demonstrated in 77% of M. abscessus subsp. abscessus and 69% of M. abscessus subsp. massiliense isolates. Among the 6 clarithromycin-resistant (MICs ≥ 8 mg/liter) M. abscessus subsp. abscessus isolates, the combination of rifabutin and clarithromycin was 100% synergistic. Rifabutin showed promising in vitro synergism with first-line anti-M. abscessus agents, especially for macrolide-resistant M. abscessus subsp. abscessus isolates.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article